Oncology
- DISEASE INDICATIONS: Lung Cancer
- MANUFACTURER: AstraZeneca AB
- USAGE: Oral
- MEDICINE APPROVED BY:
- European Medical Agency (EMA)
- Food and Drug Administration (FDA)
- Health Canada
- Therapeutic Goods Administration (TGA)
- Medsafe (NZ)
Tagrisso, with the generic name osimertinib, is a prescription medication used in the treatment of non-small cell lung cancer (NSCLC).
$5,720.00
Select optionsThis product has multiple variants. The options may be chosen on the product page